Drug intelligence / Profile preview

irinotecan hydrochloride liposome injection + temozolomide + vincristine

Development stage: Unknown
Lead developer: CSPC Pharmaceutical Group
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous, Oral

Overview

NALIRI-VT is an investigational combination chemotherapy regimen comprising irinotecan hydrochloride liposome injection, temozolomide, and vincristine. Developed under the leadership of Tang Xiaodong for the treatment of advanced Ewing's sarcoma, this regimen utilizes a nanoliposomal formulation of irinotecan to improve the drug's pharmacokinetic profile and intratumoral concentration. Irinotecan acts by inhibiting DNA topoisomerase I, leading to lethal DNA strand breaks during replication. Temozolomide, an oral alkylating agent, further contributes to DNA damage by methylating guanine residues. Vincristine, a vinca alkaloid, disrupts microtubule assembly, causing mitotic arrest. This triplet combination is currently being evaluated in a randomized Phase 2 clinical trial (NALIRI-VT vs. VIT) to determine if the liposomal formulation of irinotecan offers superior efficacy and safety compared to standard irinotecan in patients who have failed first-line therapy.

Other names: Nanoliposomal Irinotecan + Vincristine + Temozolomide

Targets

TUBB (Tubulin (alpha and beta subunits))TOP1 (DNA Topoisomerase I)DNA

Beyond the preview

Go deeper on irinotecan hydrochloride liposome injection + temozolomide + vincristine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on irinotecan hydrochloride liposome injection + temozolomide + vincristine.

Explore the full profile